Using the CombiCell platform with our expertise in immune cell activation, we have been able to design synthetic surface molecules that significantly enhance the sensitivity of CARs and TCRs against high-value targets.  We are building on this success, applying our technology to a range of hard-to-target and proprietary antigens.

Come back soon to see our progress and full pipeline!